Claim 1: a developing Tank which comprises a trialquilo citrate and / or acetyl Citrate trialquilo, wherein the alkyl groups of each of the trialquilo citrate and acetyl Citrate trialquilo are same or different, and have a number of Atoms Carbon between 3 and 5.8: the formulation of demand Deposit according to claim 4, wherein the Drug Is nepafenac, dexamethasone, indomethacin, diclofenac sodium, levofloxacin, incb28050, Cyclosporin a, timolol maleate, Fluocinolone Acetonida, Triamcinolone Acetonida, budeso Nida, olopatadine, Latanoprost,(6 - ((4 - (pyrazol-1-yl) benzyl] (pyridin - 3 - ilsulfonil) aminomethyl} pyridin - 2 - isopropyl acetate, ilamino) [2 - [[2 - [(hidroxiacetil) amino] - 4 - piridinil] methyl] thio] - N - [4 - (trifluoromethoxy) phenyl] - 3-pyridinecarboxamide, or sirolimus.10: the formulation of demand Deposit according to any one of claims 1 to 8, characterized in that it comprises at least 0.1% (Weight by weight) trialquilo citrate and / or Citrate acetyl trialquilo.12: the formulation of demand Deposit according to claim 11, wherein the formulation of Warehouse is for intravitreal Administration, administration or Subconjunctival intracameral Administration.Claim 14: a method for the formation of a Tank, characterized in that it comprises the following Procedure: Put a Fluid composition which contains a trialquilo citrate and / or acetyl Citrate trialquilo in contact with water, a buffer solution of pH the FOSFA To a simulated body fluid or a Fluid Body,Where the alkyl groups of each of the trialquilo citrate and acetyl Citrate trialquilo are same or different, and have a number of carbon Atoms between 3 and 5.Reivindicación 1: Una formulación de depósito que comprende un citrato de trialquilo y/o acetil citrato de trialquilo, caracterizada porque los grupos alquilo que posee cada uno del citrato de trialquilo y el acetil citrato de trialquilo son iguales o diferentes, y tienen una cantidad de átomos de carbono de entre 3 y 5. Reivindicación
